Nonopioid Analgesics

Medical Clinics of North America

Volumn 91, Issue 1, 2007, Pages 97-111

  Munir, Muhammad A ^a   Enany, Nasr ^a   Zhang, Jun Ming ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACTRON; CELECOXIB; CHOLINE MAGNESIUM TRISALICYLATE; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC POTASSIUM; DIFLUNISAL; ETODOLAC; FENOPROFEN; FENOPROFEN CALCIUM; IBUPROFEN; INDOCHRON; INDOMETACIN; KETOPROFEN; KETOROLAC; MEFENAMIC ACID; MELOXICAM; MISOPROSTOL; MORPHINE; NABUMETONE; NAPROXEN; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PARACETAMOL; PIROXICAM; PROTON PUMP INHIBITOR; ROFECOXIB; SALICYLIC ACID; SULINDAC; TOLMETIN; TRICOSAL; UNINDEXED DRUG; VALDECOXIB;

ABDOMINAL PAIN; ANALGESIA; ANALGESIC NEPHROPATHY; ANEMIA; ANGIONEUROTIC EDEMA; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; ASTHMA; BLEEDING; BRONCHOSPASM; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC PAIN; CLINICAL TRIAL; COLON CANCER; CONFUSION; DEPRESSION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DEPENDENCE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TOLERANCE; DRUG WITHDRAWAL; DUODENUM ULCER; EDEMA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HALLUCINATION; HEART INFARCTION; HOT FLUSH; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERVENTILATION; HYPOTENSION; INFLAMMATION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; LARYNX EDEMA; LIVER NECROSIS; LIVER TOXICITY; LOW DRUG DOSE; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; NAUSEA; NONHUMAN; OSTEOARTHRITIS; PAIN; PAIN ASSESSMENT; PATENT DUCTUS ARTERIOSUS; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PSYCHOSIS; RECOMMENDED DRUG DOSE; RESPIRATION DEPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SEIZURE; SEIZURE THRESHOLD; SHOCK; SIDE EFFECT; SODIUM RETENTION; STOMACH DISEASE; STOMACH HEMORRHAGE; STOMACH INJURY; STOMACH ULCER; STROKE; SUICIDE; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; URIC ACID URINE LEVEL; URTICARIA; VASODILATATION; VASOMOTOR RHINITIS; VERTIGO; WATER RETENTION;

ANALGESICS, NON-NARCOTIC; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; PAIN; SALICYLATES;

EID: 33845308836     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2006.10.011     Document Type: Review

References (29)

1. Acute Pain Management Guideline Panel. Acute pain management: operative or medical procedures and trauma: clinical practice guidelines (1992), Agency for Healthcare Policy and Research, Public Health Service, US Department of Health and Human Services, Rockville (MD)
2. Carr D., and Goudas L. Acute pain. Lancet 353 (1999) 2051-2058
3. Zuckerman L., and Ferrante F. Nonopioid and opioid analgesics. In: Ashburn M., and Rice L. (Eds). The management of pain (1998), Churchill-Livingstone, Philadelphia (PA) 111-140
4. McCormack K. Non-steroidal anti-inflammatory drugs and spinal nociceptive processing. Pain 59 (1994) 9-43
5. Vane J. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 234 (1971) 231-238
6. Malmberg A., and Yaksh T. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science 257 (1992) 1276-1279
7. Chandrasekharan N., Dai H., Roos K., et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 99 (2002) 13926-13931
8. Deeks J.J., Smith L.A., and Bradley M.D. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 325 (2002) 619-626
9. Rostom A., Dube C., Wells G., et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 4 (2002) CD002296
10. McAdam B.F., Catella-Lawson F., Mardini I.A., et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (cox)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 96 (1999) 272-277
11. Catella-Lawson F., McAdam B., Morrison B.W., et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 289 (1999) 735-741
12. FitzGerald G.A. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2 (2003) 879-890
13. Bresalier R.S., Sandler R.S., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
14. Nussmeier N.A., Whelton A.A., Brown M.T., et al. Complications of COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352 (2005) 1081-1091
15. Solomon S.D., McMurray J.V., Pfeffer M.A., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
16. Pitt B., Pepine C., and Willerson J.T. Cyclooxygenase-2 inhibition and cardiovascular events. Circulation 106 (2002) 167-169
17. Cheng H.F., and Harris R.C. Cyclooxygenases, the kidney, and hypertension. Hypertension 43 (2004) 525-530
18. Patrono C., and Dunn M.J. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 32 (1987) 1-12
19. Ehrlich G. Primary drug therapy: aspirin vs. the nonsteroidal anti-inflammatory drugs. Postgrad Med May Spec (1983) 9-17
20. Stuart J.J., and Pisko E.J. Choline magnesium trisalicylate does not impair platelet aggregation. Pharmatherapeutica 2 8 (1981) 547-551
21. Whitcomb D., and Block G. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA 272 (1994) 1845-1850
22. Food and Drug Administration. Over-the-counter drug products containing analgesic/antipyretic active ingredients for internal use; required alcohol warning; final rule; compliance date. Food and Drug Administration, HHS, Fed Regist 1999;64(51):13066-7.
23. Hylek E., Heiman H., Skates S., et al. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 279 (1998) 657-662
24. Panara M.R., Renda G., Sciulli M.G., et al. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J Pharmacol Exp Ther 290 (1999) 276-280
25. Patoia L., Santucci L., Furno P., et al. A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers. B Brit J Rheumatol 35 (1996) 61-67
26. Patrignani P., Panara M.R., Greco A., et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 271 (1994) 1705-1712
27. Scott D.L., and Palmer R.H. Safety and efficacy of nabumetone in osteoarthritis: emphasis on gastrointestinal safety. Aliment Pharmacol Ther 14 (2000) 443-452
28. Furberg C.D., Psaty B.M., and FitzGerald G.A. Parecoxib, valdecoxib and cardiovascular risk. Circulation 111 (2005) 249
29. FitzGerald G.A. Coxibs and cardiovascular disease. N Engl J Med 351 (2004) 1709-1711